Treatment outcomes for up to 2 years in patients aged <12 years with inadequately controlled moderate-to-severe atopic dermatitis: Real-world data from PEDISTAD

Hidradenitis Suppurativa: Clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism – A Prospective Cohort Study

PD-1 inhibitor induced skin reactions

Real-world evidence for guselkumab treatment of severe psoriasis: A sub-group analysis of efficacy and drug survival from the Australasian Psoriasis Registry

Resistant case of pressure induced urticaria treated with Adalimumab

Effectiveness of biologics in clinical practice in Australian patients: Week 12 primary outcomes from the international observational psoriasis study of health outcomes (PSoHO)

Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

Bimekizumab early treatment response translates into cumulative health-related quality of life benefits in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials